Posted March 11, 2020
Proving Autologous Skincare is the Future of Aesthetic Treatments and Products
SoME™ SKINCARE AND AESTHETICS BIOMEDICAL ANNOUNCES ISSUANCE OF U.S. PATENT FOR BIOLOGIC PRESERVING COMPOSITION AND METHODS OF USE
At Aesthetics Biomedical, our scientific findings are making a major contribution to the growing field of regenerative aesthetics. Under this patent, we will continue expanding the field of knowledge where one may utilize their own autologous biologics to improve areas of concern, naturally.
PHOENIX (PRWEB) MARCH 11, 2020
Aesthetics Biomedical Inc, a company committed to the development and distribution of innovative aesthetic devices, products, and services for the global market, announces issuance of U.S. Patent for Biologic Preserving Composition and Methods of Use. The United States Patent and Trademark Office has issued Aesthetics Biomedical the U.S. Patent No. 16/440,774 which covers topical compositions for combining biologics with skincare.
The issuance of this patent comes just months after the company launched the proprietary SoME™ Skincare product. SoME™ is the first of its kind topical product that provides the cosmetic base that can be combined with autologous platelet rich plasma (PRP) creating a personal product for home use. Immediately upon launch, this clinically proven product was met with positive response from physicians and patients alike. This patent, further positions Aesthetics Biomedical’s SoME™ Skincare brand at the forefront of innovation in the physician dispensed topical-use skincare product category.
“Aesthetics Biomedical is very focused on conducting critical science that supports both our topical products and aesthetic devices. Thanks in large part to our research and product development teams, our scientific findings are already making a major contribution to the growing field of regenerative aesthetics. Under this patent, and the patents we have pending, we will continue expanding the field of knowledge where one may utilize their own autologous biologics to improve areas of concern, naturally.” says MaryAnn Guerra, CEO & President of Aesthetics Biomedical.
Shaun Wootten, Director of Research & Development at Aesthetics Biomedical and inventor continues, “The issuance of this patent protecting Aesthetics Biomedical’s product development is invigorating in both scope and impact in this growing field of regenerative medicine. We aim to be leaders in driving new knowledge relating to not only PRP, but other autologous biologics as well in improving personalized treatments for the consumer.”
The field of regenerative aesthetics is rapidly expanding as both physicians and patients are increasingly interested in the use of PRP to effectively achieve aesthetic outcomes. This patent simultaneously protects the investments of our physicians and cements Aesthetics Biomedical’s place as the leading force for clinical science in the autologous skincare category.
Visit AestheticsBiomedical.com or SoMESkincare.com for more information, or to find a physician provider near you.
About Aesthetics Biomedical
Aesthetics Biomedical is committed to the development and distribution of innovative aesthetic devices, products, and services for the global market. ABM creates novel patient treatment experiences that ensure our products yield desired results, keeping patient comfort in mind. Aesthetics Biomedical’s SoME™ products are intended to meet the FDA’s definition of a cosmetic; an article applied to the human body to cleanse, beautify, promote attractiveness, and alter appearances. ABM products do not contain platelet rich plasma and are not intended to be drug or biologic products that diagnose, treat, cure, or prevent any disease or condition. These products have not been approved by the FDA, and the statements on these products have not been evaluated by the FDA.
MARKETING CONTACT: Sheldon Larson
PRESS CONTACT: Courtney Frappier